Acute pharmacological treatments for migraine: A systematic review with Mexican healthcare perspective
Abstract
Introduction Migraine is a common and disabling neurological disorder that requires effective acute treatment. However, access to optimal therapies varies significantly across healthcare systems worldwide. This systematic review assesses acute pharmacological treatments for migraine from a Mexican healthcare perspective, focusing on drug availability and proposing a practical treatment algorithm. Methods Following PRISMA guidelines, we systematically searched multiple databases from inception to November 2024. We included randomized controlled trials evaluating acute treatments for migraine in adults. Treatment efficacy data were synthesized narratively in accordance with the International Headache Society guidelines. Drug availability in Mexico was assessed through regulatory databases and clinical practice surveys. Results Thirty-six randomized controlled trials met inclusion criteria, evaluating triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), calcitonin gene-related peptide antagonists, ditans, and combination therapies. Subcutaneous sumatriptan demonstrated high efficacy (83% pain relief at 2 hours), but it is limited in availability within the Mexican public healthcare system. Oral triptans (sumatriptan, zolmitriptan, eletriptan, and rizatriptan) are available; however, access varies between the public and private sectors. NSAIDs like ketorolac and ketoprofen show good efficacy and are widely accessible. Newer agents (rimegepant, lasmiditan) are available but…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.